Medication info
Sitagliptin and Metformin Extended-Release Tablets 50/1000 mg

Sitagliptin and Metformin Extended-Release Tablets 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Bright green, oval, biconvex, extended-release film-coated tablets
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201883 · Approved 2022.05.09 · Insurance code 642906760

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this product should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. The 100/1000 mg extended-release tablet of this product is taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this product take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this product for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching to this product from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this product's 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this product. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this product must be discontinued immediately.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes

View approved original text

This medication helps control blood sugar levels in patients with Type 2 diabetes by taking sitagliptin and metformin together. When used alongside meal planning and exercise therapy, it aids in effectively improving blood sugar levels. This supports the stable management of diabetes symptoms.

How to take

Adult dose

In antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this product should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. The 100/1000 mg extended-release tablet of this product is taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this product take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this product for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching to this product from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this product's 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this product. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this product must be discontinued immediately.

Precautions

This medication contains sitagliptin and metformin and is used for diabetes treatment. First, there may be hypersensitivity reactions upon taking this medication; therefore, if symptoms of allergy, skin rash, or difficulty breathing occur, discontinue use immediately and consult a doctor. Additionally, serious side effects such as acute pancreatitis have been reported, so if abdominal pain, vomiting, or severe abdominal discomfort occurs after taking this medication, notify medical personnel immediately. This medication should not be used in patients with reduced kidney function, and regular assessments of kidney function should be conducted to ensure it is normal. It should especially be avoided in cases of moderate or severe kidney dysfunction, dehydration, severe infections, or heart problems. Patients with acute heart failure or acute myocardial infarction, or those scheduled for examinations using radiographic contrast media containing iodine should also not use this medication. It is advisable not to use this medication in pregnant women or those who may become pregnant, and in nursing mothers, as safety is uncertain. This medication lowers blood sugar; hence, one should be attentive to symptoms of hypoglycemia, as the risk may increase when taking it with other blood sugar-lowering drugs. Patients who exercise heavily or have irregular meal intakes may face a higher risk of hypoglycemia, necessitating careful monitoring. It is recommended to avoid alcohol while taking this medication, as it may increase the risk of serious side effects such as lactic acidosis. Patients with liver dysfunction should avoid this medication and regularly monitor liver and kidney function. Those scheduled for surgery or in a severely ill condition due to infections or trauma should temporarily discontinue use until recovery. Rarely, there may be severe joint pain, skin disorders, or muscle pain as side effects; if such symptoms occur, consult a doctor. Lastly, this medication should not be used in children under 18 years as safety and efficacy have not been sufficiently established. Regular tests of blood sugar, kidney function, and vitamin B12 levels should be conducted while using this medication, and any adverse effects should prompt immediate consultation with medical personnel.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 16 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is important to keep the storage temperature between 1 and 30 degrees Celsius to maintain the medication's effectiveness safely over time.

Appearance and packaging

Appearance

Bright green, oval, biconvex, extended-release film-coated tablets

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.